Literature DB >> 35557592

miRNA-320 inhibits colitis-associated colorectal cancer by regulating the IL-6R/STAT3 pathway in mice.

Meng-Yao Wu1, Yu-Xin Luo1, Wen-Xiu Jia1, Dan-Dan Wang1, Dong-Lei Sun1, Jia Song1, Jing Wang1, Wei-Wei Niu1, Xiao-Lan Zhang1.   

Abstract

Background: Colitis-associated colorectal cancer (CAC) is a serious complication of inflammatory bowel disease (IBD). microRNA-320 (miRNA-320) promotes intestinal mucosal barrier repair in IBD and inhibits tumor progression. However, the role of miRNA-320 in the progression of CAC remains to be defined. We studied the mechanisms of miRNA-320 in the progression of CAC in mice.
Methods: CAC was induced in mice (C57BL/B6) by the administration of azoxymethane (AOM) and dextran sulfate sodium (DSS), and the mice were given a lentiviral vector (LV) overexpressing mmu-miRNA-320. The level of miRNA-320 was analyzed by quantitative real-time polymerase chain reaction (qPCR). Colonic inflammation, histological analysis, and tumorigenesis were evaluated. Ki-67 in colonic tissues was examined by immunohistochemistry. B-cell lymphoma-extra large (BCL-xl) and proliferating cell nuclear antigen (PCNA) expression was examined by Western blot. Furthermore, the proliferation, migration, and invasion of colorectal cancer (CRC) cells were evaluated. The levels of interleukin-6 receptor (IL-6R), signal transducer and activator of transcription 3 (STAT3), and phosphorylated-signal transducer and activator of transcription 3 (p-STAT3) were examined by Western blot and qPCR.
Results: miRNA-320 was downregulated in CAC mice (0.57±0.13 vs. 1.00±0.12, t=-5.95, P<0.001). miRNA-320 decreased the disease activity index (DAI) scores, improved colonic inflammation, and inhibited tumor formation (tumor number: 8.00±2.90 vs. 13.67±2.73, t=-3.49, P<0.01) in mice with CAC. miRNA-320 suppressed the expression of BCL-xl, PCNA, and Ki-67 (0.38±0.07 vs. 0.69±0.08, t=-7.30, P<0.001). miRNA-320 inhibited colon cancer cell proliferation, migration, and invasion. miRNA-320 significantly inhibited the levels of IL-6R [colon tissue messenger RNA (mRNA): 4.06±1.44 vs. 10.05±1.55, t=-6.94, P<0.001], STAT3, and p-STAT3 in vivo and in vitro. Silencing IL-6R expression partially reversed the IL-6R/STAT3-suppressing and tumor-inhibiting effect of miRNA-320. Conclusions: miRNA-320 inhibits tumorigenesis in mice with CAC by suppressing IL-6R/STAT3 expression, and IL-6R is a target gene of miRNA-320. 2022 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Inflammatory bowel disease (IBD); colitis-associated colorectal cancer (CAC); interleukin-6 receptor (IL-6R); microRNA-320 (miRNA-320); signal transducer and activator of transcription 3 (STAT3)

Year:  2022        PMID: 35557592      PMCID: PMC9086045          DOI: 10.21037/jgo-22-237

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  29 in total

1.  miR-320 regulates tumor angiogenesis driven by vascular endothelial cells in oral cancer by silencing neuropilin 1.

Authors:  Yi-Ying Wu; Yuh-Ling Chen; Yun-Chia Jao; I-Shan Hsieh; Kung-Chao Chang; Tse-Ming Hong
Journal:  Angiogenesis       Date:  2013-10-10       Impact factor: 9.596

2.  Decreased miR-320 expression is associated with breast cancer progression, cell migration, and invasiveness via targeting Aquaporin 1.

Authors:  Liang Luo; Rui Yang; Shaojie Zhao; Yu Chen; Shanchao Hong; Ke Wang; Tiejun Wang; Jing Cheng; Ting Zhang; Daozhen Chen
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2018-05-01       Impact factor: 3.848

Review 3.  MicroRNAs, intestinal inflammatory and tumor.

Authors:  Yuan Feng; Yuan Zhang; Di Zhou; Gang Chen; Ning Li
Journal:  Bioorg Med Chem Lett       Date:  2019-06-12       Impact factor: 2.823

4.  TEL-AML1 regulation of survivin and apoptosis via miRNA-494 and miRNA-320a.

Authors:  Christofer Diakos; Sheng Zhong; Yuanyuan Xiao; Mi Zhou; Gisele M Vasconcelos; Gerd Krapf; Ru-Fang Yeh; Shichun Zheng; Michelle Kang; John K Wiencke; Maria S Pombo-de-Oliveira; Renate Panzer-Grümayer; Joseph L Wiemels
Journal:  Blood       Date:  2010-08-31       Impact factor: 22.113

Review 5.  MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.

Authors:  Rajesha Rupaimoole; Frank J Slack
Journal:  Nat Rev Drug Discov       Date:  2017-02-17       Impact factor: 84.694

Review 6.  Cancer risk after resection of polypoid dysplasia in patients with longstanding ulcerative colitis: a meta-analysis.

Authors:  Linda K Wanders; Evelien Dekker; Bo Pullens; Paul Bassett; Simon P L Travis; James E East
Journal:  Clin Gastroenterol Hepatol       Date:  2013-08-03       Impact factor: 11.382

7.  Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study.

Authors:  Livia Biancone; Alessandro Armuzzi; Maria Lia Scribano; Fabiana Castiglione; Renata D'Incà; Ambrogio Orlando; Claudio Papi; Marco Daperno; Maurizio Vecchi; Gabriele Riegler; Walter Fries; Patrizia Alvisi; Gianmichele Meucci; Filippo Mocciaro; Francesca Rogai; Stefano Festa; Luisa Guidi; Anna Testa; Luisa Spina; Sara Renna; Anna Viola; Marta Patturelli; Roberto Di Mitri; Iris Frankovic; Emma Calabrese; Carmelina Petruzziello; Elena De Cristofaro; Giorgia Sena; Alessandra Ruffa; Benedetto Neri; Alessandra Rossi
Journal:  Inflamm Bowel Dis       Date:  2020-02-11       Impact factor: 5.325

8.  Strain-specific suppression of microRNA-320 by carcinogenic Helicobacter pylori promotes expression of the antiapoptotic protein Mcl-1.

Authors:  Jennifer M Noto; M Blanca Piazuelo; Rupesh Chaturvedi; Courtney A Bartel; Elizabeth J Thatcher; Alberto Delgado; Judith Romero-Gallo; Keith T Wilson; Pelayo Correa; James G Patton; Richard M Peek
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-10-17       Impact factor: 4.052

9.  Histone Deacetylase Inhibition in Prostate Cancer Triggers miR-320-Mediated Suppression of the Androgen Receptor.

Authors:  Shinya Sato; Keisuke Katsushima; Keiko Shinjo; Akira Hatanaka; Fumiharu Ohka; Shugo Suzuki; Aya Naiki-Ito; Norihito Soga; Satoru Takahashi; Yutaka Kondo
Journal:  Cancer Res       Date:  2016-05-23       Impact factor: 12.701

10.  IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair.

Authors:  Loris R Lopetuso; Carlo De Salvo; Luca Pastorelli; Nitish Rana; Henry N Senkfor; Valentina Petito; Luca Di Martino; Franco Scaldaferri; Antonio Gasbarrini; Fabio Cominelli; Derek W Abbott; Wendy A Goodman; Theresa T Pizarro
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.